Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

38.62USD
21 Aug 2019
Change (% chg)

$0.62 (+1.63%)
Prev Close
$38.00
Open
$38.33
Day's High
$38.66
Day's Low
$37.45
Volume
111,633
Avg. Vol
188,839
52-wk High
$60.98
52-wk Low
$36.19

Vitullo, Nicole 

Ms. Nicole Vitullo is a Lead Independent Director of Esperion Therapeutics, Inc. She joined Domain Associates, LLC, a venture capital firm with an exclusive focus on life sciences, in 1999 and became a Partner in 2004. From 1992 to 1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. Ms. Vitullo is a director of a number of companies including Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), Celtaxsys Inc. and Cotera, Inc. She previously served on the boards of Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals), Durata Therapeutics (acquired by Actavis PLC) and VentiRx Pharmaceuticals (acquired by Celgene, Inc.). Ms. Vitullo received a B.A. and an M.B.A. from the University of Rochester. We believe Ms. Vitullo's experience working with and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry qualifies her to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 59,317
Fiscal Year Total, USD 403,163

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --